Skip to content

Nabriva Therapeutics plc

CIK 0001641640

← back to feed
Revenue (TTM)
$28.18M
+27.8% YoY Q2 Sep 2023
Net Income (TTM)
−$43.35M
−15.6% YoY Q2 Sep 2023
EPS Diluted (TTM)
−$15.04
+25.2% YoY Q2 Sep 2023
Gross Margin
20.6%
Q2 Sep 2023
Operating Margin
-149.4%
Q2 Sep 2023
Net Margin
-153.8%
Q2 Sep 2023
Free Cash Flow (TTM)
−$71.45M
Q2 Sep 2023
Cash
$2.18M
Q2 Sep 2023
Total Debt
$540K
Q2 Sep 2023
Shares Outstanding
3.23M sh
Q2 Sep 2023

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings